PHA Classroom banner

>>Back to All Recordings

>>Back to About PH Recordings
>>Back to 2012 Conference Session Recordings

Session Recording from PHA's 2012 10th International PH Conference
Inhaled Therapies for PAH

June 24, 2012

Prostacyclins are highly effective medications for treating PAH. In the past, prostacyclins had to be given directly through a catheter into a vein or under the skin. There are now two FDA-approved prostacyclins that are given by the inhaled route (iloprost, treprostinil). There are also three oral medications being studied that affect the prostacyclin pathway: two prostacyclins (treprostinil, beraprost) and one medication that acts similar to prostacyclins by activating the prostacyclin receptor. This session will review the safety and benefits of inhaled prostacyclins and outline the current research on oral prostacyclins.

Presenter Information

Ivan Robbins, MD, Vanderbilt University, Nashville, Tenn. (Chair); Kimberly Farmer, RN, BSN, Vanderbilt University Medical Center, Nashville, Tenn.; Gautam Ramani, MD, University of Maryland, Baltimore, Md.; James Runo, MD, University of Wisconsin, Madison, Wisc.








Actelion Pharmaceuticals US, Inc. Gilead Sciences, Inc. United Therapeutics Corporation Bayer HealthCare
This is a program of the PHA Medical Education Fund, made possible through unrestricted educational grants from our supporters.


FacebookGoogle +TwitterLinkedInPinterestInstagramYouTubeBloggerFeedsPHAware Download our App

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
    Privacy Policy    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.® | © 2015 Pulmonary Hypertension Association. All Rights Reserved.


The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.